Abstract
Since the first successful cord blood transplant was performed in 1988 there has been a gradual increase in the use of cord blood for hemopoietic stem cell transplantation. Worldwide, over 8,000 unrelated cord blood transplants have been performed with the majority being for children with hemopoietic malignancies. Transplantation for adults has increased but is limited by the low number of nucleated cells and CD34+ cells within a single cord blood collection. Cord blood hemopoietic stem cells are more primitive than their adult counterparts and have high proliferative potential. Cord blood ex vivo expansion is designed to improve transplant outcomes by increasing the number of hemopoietic stem cells with long term repopulating potential and their differentiated progeny. However, despite a large amount of research activity during the last decade, this aim has not been realized. Herein we discuss the rationale for this approach; culture methods for ex vivo expansion, ways to assess the functional capacity of ex vivo generated hemopoietic stem cells and clinical outcomes following transplantation with ex vivo expanded cord blood.
Keywords: Stem cells, cord blood, ex vivo expansion, transplantation
Current Stem Cell Research & Therapy
Title: Expansion of Umbilical Cord Blood for Clinical Transplantation
Volume: 2 Issue: 4
Author(s): David N. Haylock and Susan K. Nilsson
Affiliation:
Keywords: Stem cells, cord blood, ex vivo expansion, transplantation
Abstract: Since the first successful cord blood transplant was performed in 1988 there has been a gradual increase in the use of cord blood for hemopoietic stem cell transplantation. Worldwide, over 8,000 unrelated cord blood transplants have been performed with the majority being for children with hemopoietic malignancies. Transplantation for adults has increased but is limited by the low number of nucleated cells and CD34+ cells within a single cord blood collection. Cord blood hemopoietic stem cells are more primitive than their adult counterparts and have high proliferative potential. Cord blood ex vivo expansion is designed to improve transplant outcomes by increasing the number of hemopoietic stem cells with long term repopulating potential and their differentiated progeny. However, despite a large amount of research activity during the last decade, this aim has not been realized. Herein we discuss the rationale for this approach; culture methods for ex vivo expansion, ways to assess the functional capacity of ex vivo generated hemopoietic stem cells and clinical outcomes following transplantation with ex vivo expanded cord blood.
Export Options
About this article
Cite this article as:
Haylock N. David and Nilsson K. Susan, Expansion of Umbilical Cord Blood for Clinical Transplantation, Current Stem Cell Research & Therapy 2007; 2 (4) . https://dx.doi.org/10.2174/157488807782793745
DOI https://dx.doi.org/10.2174/157488807782793745 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Quality of Life in Patients with β-thalassemia Major: Short-term and Long-term Effects After Haematopoietic Stem Cell Transplantation
Current Stem Cell Research & Therapy Novelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
Cardiovascular & Hematological Agents in Medicinal Chemistry Tumor-Derived Exosomes Contain microRNAs with Immunological Function: Implications for a Novel Immunosuppression Mechanism
MicroRNA 5q- syndrome
Current Pharmaceutical Design LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology Diagnostic Methods in the Detection of Prostate Cancer: Prospective Observational Study
Current Medical Imaging Developing Target Therapy Against Oncogenic Tyrosine Kinase in Myeloid Maliganacies
Current Pharmaceutical Biotechnology Editorial [Hot Topic: New Treatment Strategy of the Myelodysplastic Syndromes]
Current Pharmaceutical Design Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Primary Lung Lymphoma
Current Drug Targets - Inflammation & Allergy Invasive Fungal Infection in Febrile Patients with Hematologic Malignancies Undergoing Chemotherapy in Iran
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery The Adenine Nucleotide Translocase 2, a Mitochondrial Target for Anticancer Biotherapy
Current Drug Targets Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments
Current Clinical Pharmacology BK Polyoma Virus Nephropathy in an Immunocompromised Host
New Emirates Medical Journal The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews